The purpose of this study is to evaluate the efficacy and safety of association of metronidazole, nystatin and dexamethasone in the treatment of bacterial and fungal vaginal infections.

Inclusion Criteria:

• Post-menarche women and premenopausal women, between 18 and 50 years old;
• Diagnosis of bacterial vaginosis (Amsel criteria), fungal (positive KOH test)or mixed vaginal infection;
• Patients who have regular menstrual cycles (patients with regular menstrual cycles with intervals between 21 to 35 days, duration of 1 to 7 days)

Exclusion Criteria:

• Patients who have a known hypersensitivity to components of the formula ;
• Pregnant and lactating women ;
• Patients with other vaginal infections, such as infection by Trichomonas vaginalis , C. trachomatis, Neisseria gonorrhoeae , herpes or HPV.
• Knowledge of positive test result for human immunodeficiency virus ;
• Patients in treatment of cervical intraepithelial neoplasia or carcinoma of the cervix ;
• Patients who have undergone gynecological procedures in the month prior to inclusion (such as cauterization of the cervix , cervical biopsy, high-frequency surgery) ;
• Patients with other vaginal or vulvar conditions that may confound interpretation of clinical response;
• Patients who received intravaginal or systemic antimicrobial or antifungal therapy 14 days before randomization ;
• Patients on immunosuppressive medications (such as corticosteroids , cyclosporine , etc. ) ;
• Known or suspected cancer ;
• Participation in any experimental study or ingestion of any experimental drug 12 months before the start of this study.